Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy

doi:10.4251/wjgo.v13.i8.915

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4644)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

303

WORD

124

HTML

2273

Figures (1-3)

281

Tables (1-4)

258

Sum=3239

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

433

Download

972

Sum=1405

Aug 15, 2021 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Aug 15, 2021; 13(8): 915-928
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.915

Full Size Figure Download Figure

Figure 1 Overall survival and progression-free survival. A and B: Overall survival (A) and progression-free survival (B) of the following groups: Carbohydrate antigen 19-9 (CA19-9) responder group, CA19-9 non-responder group and CA19-9-negative group. CA19-9 responder group and CA19-9 negative group showed significantly longer overall survival and progression-free survival than CA19-9 non-responder group. CA19-9: Carbohydrate antigen 19-9.

Citation: Shin K, Jung EK, Park SJ, Jeong S, Kim IH, Lee MA. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. World J Gastrointest Oncol 2021; 13(8): 915-928
URL: https://www.wjgnet.com/1948-5204/full/v13/i8/915.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.915